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We have shown previously that granulocyte-macro-
phage colony-stimulating factor-stimulated mouse 
bone marrow-derived MIIC class II+ dendritic cell 
(DC) progenitors that are deficient in cell surface ex-
pression of the costimulatory molecules B7-1 (CD80) 
and B7-2 (CD86) can induce alloantigen-specific T-cell 
anergy in vitro. To test the in vivo relevance of these 
findings, 2x 106 BI0 (H2b) mouse bone marrow-derived 
DC progenitors (NLDC 145+, MIIC class II+, B7-1ditn, 
B7_2-/dim) that induced T-cell hyporesponsiveness in 
vitro were injected systemically into normal C3H 
(H2k) recipients. Seven days later, the mice received 
heterotopic heart transplants from BI0 donors. No im-
munosuppressive treatment was given. Median graft 
survival time was prolonged significantly from 9.5 to 
22 days. Median graft survival time was also in-
creased, although to a lesser extent (16.5 days), in mice 
that received third-party (BALB/c; H2d ) DC progeni-
tors. Ex vivo analysis of host T-cell responses to donor 
and third-party alloantigens 7 days after the injection 
of DC progenitors (the time of heart transplant) re-
vealed minimal anti-donor mixed leukocyte reaction 
and cytotoxic T lymphocyte reactivity. These re-
sponses were reduced substantially compared with 
those of spleen cells from animals pretreated with 
"mature" granulocyte-macrophage colony-stimulating 
factor + interleukin-4-stimulated DC (MHC class 
nbr'ght, B7-1 +, B7_2brlght), many of which rejected their 
heart grafts in an accelerated fashion. Among the in-
jected donor MHC class 11+ DC progenitors that mi-
grated to recipient secondary lymphoid tissue were 
cells that appeared to have up-regulated cell surface 
B7-1 and B7-2 molecule expression. This observation 
may explain, at least in part, the temporary or unsta-
ble nature of the hyporesponsiveness induced by the 
DC progenitors in nonimmunosuppressed recipients. 
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The discovery in 1992 of multilineage leukocyte microchi-
merism many years after organ transplantation (1, 2) im-
plied the migration and survival of donor progenitor or even 
stem cells within recipient tissues. A prominent donor leu-
kocyte, both in these clinical observations and in experimen-
tal animal studies (3, 4), has been the dendritic cell (DC*). 
These bone marrow (BM)-derived leukocytes are the most 
potent known antigen-presenting cells (APC). They have the 
unique capacity to activate resting, naive T lymphocytes (5). 
In addition, however, tolerogenic properties of DC have been 
described both in vitro (6, 7) and in vivo (8, 9). Recently, we 
reported that donor-derived DC progenitors can be propa-
gated in vitro from the BM of unmodified mice that perma-
nently accept MHC-incompatible liver transplants, but not 
from the lymphoid tissue of animals that acutely reject heart 
grafts (10). The in vivo functional relevance of donor-derived 
DC progenitors has not been established. It has been sug-
gested that, in sufficient numbers, these chimeric APC may 
playa role in the induction of transplantation tolerance (1-4, 
10,11). 
The functional maturation of DC and other APC, such as 
macro phages or activated B cells, has been shown to depend 
on the cytokine-induced up-regulation of cell surface MHC 
class II and T-cell "costimulatory" molecules, particularly the 
CD28 ligands B7-1 (CD80) and B7-2 (CD86) (12, 13). We 
hypothesized that in accordance with the "two-signal" hy-
pothesis ofT-cell activation (14), failure ofMHC class II+ DC 
progenitors to deliver essential costimulatory signals might 
result in a state of induced unresponsiveness (anergy). DC 
propagated from normal mouse BM in response to granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) + in-
terleukin (11)-4 ("mature" DC) are potent inducers of alloge-
neic T-cell activation. In contrast. costimulatory molecule-
deficient DC progenitors (MHC class 11+, B7_1dim. B7-2-) 
grown in low concentrations of GM-CSF alone fail to stimu-
late in primary mixed leukocyte reactions (MLR) and induced 
donor-specific T-cell anergy (15). In this study, we have ex-
amined the relevance of these findings to organ transplanta-
tion by administering costimulatory molecule-deficient DC 
progenitors to normal mice that subsequently received vas-
cularized cardiac allografts. The data show that pretreat-
* Abbreviations: APC. antigen-presenting cell; BM. bone marrow; 
CTL. cytotoxic T lymphocyte; DC, dendritic cell; FITC, fluorescein 
isothiocyanate; GM-CSF, granulocyte-macrophage colony-stimulat-
ing factor; IL. interleukin; MLR. mixed leukocyte reactions; MST, 
median graft survival time. 
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ment with these donor-derived cells 1 week before transplant 
prolongs graft survival. Moreover, injection of DC progeni-
tors is associated at the time of transplant with hyporespon-
siveness of host T cells to donor alloantigens. In all cases, 
hyporesponsiveness to a third party was also observed. The 
eventual graft rejection may be ascribed to in vivo up-regu-
lation of costimulatory molecule expression on donor-derived 
DC in the absence of exogenous immunosuppression. 
MATERIALS AND METHODS 
Animals. Ten- to 12-week old male C57BIlIOJ (BIO; H2b, I_Ab, 
I-E-), C3H1HeJ (C3H; H2k, I_Ak, I_Ek), and BALB/c (H2d, I_Ad, I-E+) 
mice were obtained from The Jackson Laboratory, Bar Harbor, ME. 
They were maintained in a specific pathogen-free animal facility at 
the University of Pittsburgh Medical Center. 
Propagation and purification of DC. BM cell suspensions were 
prepared in RPMI 1640 medium (Gibco, Grand Island, NY) using 
conventional procedures. The method for in vitro propagation of DC 
progenitors was modified (16) after that described initially by Inaba 
et al. (17, 18). Briefly, 2x 106 cells were cultured in 24-well plates in 
RPMI 1640 complete medium supplemented with 10% v/v heat-
inactivated fetal calf serum (Gibco) and 1000 U (4 ng)/ml recombi-
nant mouse GM-CSF either alone or together with 1000 U/ml recom-
binant mouse IL-4 (both cytokines kindly provided by Dr. S.K. 
Narula, Schering-Plough Research Institute, Kenilworth, NJ). Non-
adherent, low-buoyant density cells released spontaneously from 
proliferating cell clusters were recovered after 5-6 days of culture 
and resuspended in complete medium. They were layered onto 2-ml 
columns ofmetrizamide solution (14.5% w/v, grade I, approximately 
99% pure; Sigma Chemical Co., St. Louis, MO) sedimented at 600Xg 
at room temperature and recovered as described previously (19). The 
low-density interface (DC) population was washed twice before final 
resuspension in complete medium. Purity of the DC was verified by 
morphologic appearance of cytocentrifuge preparations (Geimsa 
staining), flow cytometric analysis, and immunocytochemical stain-
ing. An extensive panel of monoclonal antibodies was used, including 
those directed against mouse DC-restricted cell surface and intracel-
lular antigens (16,20). DC were also characterized by the presence or 
absence of phagocytic activity, using both carboxylated fluorescent 
latex microspheres (Fluoresbrite Carboxy YG, 0.5- to 3.0-/Lm diam-
eter; Polysciences Ltd., Warrington, PAl (21) and opsonized (16) 
sheep red blood cells (Remel, Lenexa, KS). Only those DC prepara-
tions with purity >80% were used. 
Flow cytometry. Cell surface immunophenotypic analysis was 
performed by cytofluorography using a F ACScan flow cytometer 
(Becton Dickinson, Mountain View. CAl. Incubation with primary 
rat monoclonal antibodies, including rat anti-NLDC 145 (22), which 
is directed against a 205-kDa protein on mouse DC (23) (a gift from 
Dr. R.M. Steinman, The Rockefeller University, New York, NY), was 
followed by fluorescein isothiocyanate (FITC)-conjugated mouse an-
ti-rat Igs, as described (16). FITC-conjugated rat anti-mouse B7-1 
(CD80) or B7-2 (CDB6) (both PharMingen, San Diego, CAl were also 
used (15). MHC class II antigen expression was identified using 
biotin-conjugated mouse anti-mouse monoclonal antibodies (PharM-
ingen) with FITC streptavidin (Jackson Immunoresearch Laborato-
ries Inc .. West Grove. PAl as the secondary reagent (JO. 16). After 
staining. the cells were fixed in 1'7c paraformaldehyde in saline 
before analysis. 
HeterotopIc heart transplantation. The method for heterotopic 
heart transplantation was adapted from the rat procedure of Ono 
and Lindsey (24). The heart was transplanted into the abdomen with 
end-to-side anastomosis of aorta to aorta and pulmonary artery to 
vena cava. Rejection was defined by the cessation of cardiac contrac-
tion after daily palpation through the abdominal wall. and confirmed 
by histological examination. No immunosuppressive therapy was 
used. To test the influence of cultured cells on heart allograft sur-
vival, 2X 106 cells were injected intravenously in 0.2 ml of medium 
via the lateral tail vein, 7 days before organ transplantation. 
Mixed leukocyte reactions. Freshly isolated splenic T cells for use 
as responder cells were prepared as described previously (16). For 
primary MLR, 2x105 T cells were cultured with graded concentra-
tions of -y-irradiated (20 Gy) allogeneic or syngeneic stimulator cells 
in 0.2 ml of RPMI 1640 complete medium and 10% fetal calf serl 1 
for 3 days in 96-well, round-bottom tissue culture plates in 5% C. " 
in air. For secondary MLR, primary cultures (2X106 T cells incu: 
bated with 106 stimulators in 24-well plates in 2 ml of culture 
medium) were harvested after 2 days, washed, and depleted of Ia + 
and nonviable cells, as described (15). The pretreated T cells were 
rested for 2 days, then restimulated with freshly isolated -y-irradi-
ated spleen cells in a secondary, a-day MLR in 96-well plates. For the 
final 18 hr of culture, 10 /LI of [3H]thymidine deoxyribose (1 /LCi) 
were added to each well. Cells were harvested onto glass fiber disks 
using a multiple cell harvester. The degree of thymidine incorpora· 
tion was determined in a liquid scintillation counter. Results were 
expressed as mean counts per minute :t 1SD. 
Cell-mediated lymphocytotoxicity assay. Freshly isolated spleen 
cells from C3H mice were cultured with 'Y-irradiated (20 Gy) alloge-
neic (B10) spleen cells (ratio 2:1) for 6 days then used as effectors, 
The EL4lymphoma cell line (H2b ; TIB39, ATCC, Rockville, MOl wa-
used as a source of target cells. The R1.l mouse lymphoma celllin( 
(H2k; TIB42, ATCC) and the P8l5 mouse mastocytoma cell line (H2d : 
TIB64, ATCC) were used as syngeneic control and third-party tar-
gets, respectively. The target cells were labeled with 100 ~Ci of 
Na251Cr 0 4 (NEN, Wilmington, DE), washed, and plated at a con· 
centration of 5 X 103 cells/well in 96-well round-bottom culture plates 
(Coming, Coming, NY). Serial, twofold dilutions of effector cells 
were added to give E:T ratios of 100:1,50:1,25:1, and 12.5:1 in a total 
volume of 200 /LVwell. The percentage of specific &lCr release was 
determined after the plates had been incubated for 4 hr at 37°C in 
10% CO2 in air. An aliquot (100 ~lF of supernatant was recovered 
from each well after centrifugation at 500g for 1 min. Maximum SlCr 
release was determined by osmotic lysis of the cells. The percent 
specific cytotoxicity was calculated using the following formula: 
experimental (cpm) - spontaneous (cpm) 
% cytotoxicity =. , x 100 
maxLmum (cpm) - spontaneous (cpm) 
The results are expressed as mean % specific 5lCr release:!: 1SD in 
triplicate cultures. 
Immunohistochemistry. Two-color immunofluorescence labeling 
of donor-derived cells in acetone-fixed cryostat sections of spleen was 
performed as described previously (4). Briefly, endogenous biotin 
was blocked with an avidin-biotin blocking reagent (Vector Labora-
tories, Inc., Burlinghame, CAl, followed by incubation with nonfat 
dried milk (each for 20 min). After two washes with phosphate-
buffered saline, the tissues were reacted for 45 min with biotinylated 
donor-specific anti-MHC class II rnAb, or with isotype-matched bi-
otinylated control Ig, then washed twice in phosphate-buffered sa-
line. The primary antibody was then localized by incubation with 
streptavidin-conjugated Cya.18 (Jackson Immunoresearch Labora-
tories) for 30 min. Cells expressing B7-1 or B7-2 molecules were 
identified by incubation (30 min) with specific FITC-conjugated rat 
anti-mouse monoclonal antibodies (PharMingen) or with irrelevant 
isotype-matched antibody (negative controll. Donor class II single 
positive cells were stained red: 87-1 or B7-2 single positive cells were 
stained green. Cytospin preparations of cultured DC were used as 
additional positive or negative controls. 
Statistics. Median graft survival times (MST) between groups 
were compared using the Kruskal-Wallis test. Pairwise comparisons 
were performed using the Wilcoxon sum rank test. P·values <0.05 
were considered statistically significant. 
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RESULTS 
Immunophenotypic analysis of GM-CSF- and GM-
CSF+IL-4-stimulated cells. The surface phenotype of cells 
released after 5-6 days from proliferating aggregates in GM-
CSF::tIL-4-stimulated BM-derived cell cultures was charac-
terized by flow cytometric analysis. Staining for cells of lym-
phoid lineage, including natural killer cells, was absent. As 
described previously, however, the floating cells stimulated 
with GM-CSF alone stained to variable degrees for surface 
antigens that are known to be associated with mouse DC (15, 
16). These included CD45 (leukocyte common antigen), MHC 
class I, heat-stable antigen (JllD), CD54 (intercellular ad· 
hesion molecule· 1), CDllb (MAC-I), and CD44 (nonpoly· 
meric determinant of Pgp.l glycoprotein). In addition, stain-
ing of low to moderate intensity was observed for the mouse 
DC-restricted cell surface markers NLDC-145 (interdigitat-
ing cells), 33Dl and CDllc (N41S; /32-integrin), for the mac-
rophage antigen F4ISO, and for Fc-yRII (CD32) (data not 
shown). As shown in Figure 1, the GM-CSF-stimulated BM· 
derived cells from BI0, C3R, and BALB/c mice also expressed 
moderate levels of cell surface MRC class II, but were B7-
1 dim (data not shown) and B7 -2 -/dim. Culture of cells in 
GM-CSF+ IL-4 augmented the intensity of staining for each 
of these molecules (Fig. 1). The expression of NLDC 145, 
MHC class II, and especially B7-2 was markedly and consis-
tently up-regulated on cells cultured for 6 to 10 days in the 
presence of both cytokines. The GM-CSF-stimulated MHC 
class II+ B7_1dim B7_2- /dim DC progenitors and the GM-
CSF+IL-4-induced MHC class 11+ B7-1+ B7_2+lbright popu-
lations are subsequently referred to herein as B7-2- and 
B7-2+ DC, respectively. 
Allostimulatory activity of "mature" (B7-2+) DC and DC 
progenitors (B7-2-) and the induction of T-cell hyporespon-
siveness. As reported previously (15), the GM·CSF+ IL-4-
stimulated BI0 BM-derived DC that were MHC class II+, 
B7-1+ and B7-2+, were highly potent inducers of primary 
allogeneic (C3H) T-cell responses in 3-day primary mixed 
leukocyte cultures (data not shown). These B7-2+ cells were 
considered to be "mature" DC. In contrast, the same numbers 
ofGM·CSF·stimulated MHC class 11+ B7-1- B7-2- BI0 BM-
derived cells were very poor inducers of allogeneic T-cell 
activation and exhibited a comparatively low level of MLR 
stimulatory activity, similar to that of bulk BlO spleen cells. 
This was consistent with their very low expression of cell 
surface B7-2. The B7-2- cells were therefore considered to be 
functionally "immature" DC. Allogeneic (C3R) T cells that 
were exposed initially for 2 days to BI0 B7-2- BM DC then 
repurified and rested for 2 days responded only weakly upon 
restimulation with BI0 spleen cells (data not shown). 
B7-2- BM-derived DC prolong cardiac allograft survival. 
We next determined whether B7-2- BM-derived DC progen-
itors could influence vascularized cardiac allograft survival 
in the absence of host immunosuppression. Graft survival 
time in untreated C3R recipients of BI0 hearts ranged from 
S to 13 days. Neither fresh allogeneic BI0 BM cells nor BlO 
B7-2+ BM-derived DC significantly affected graft survival. In 
the latter group, however, 10117 (59%) of the hearts were 
rejected in accelerated fashion within 7 days. By contrast, 
2xI06 B7-2- BI0 BM-derived DC given intravenously 7 days 
before heterotopic heart transplantation prolonged the MST 
of BI0 cardiac allografts in C3R mice from 9.5 (untreated 
recipients) to 22 days (Table 1). Interestingly, third-party 
GM-CSF GM-CSF + IL-4 
FIGURE 1. F ACScan analysis of 
NLDC-145, MHC class II, and B7-2 ex-
pression on 6-day GM-CSF and 6-day 
GM-CSF+ IL-4-stimulated BI0, C3H, 
or BALB/c BM-derived DC. Further de-
tails are provided in Materials and _~ 
Methods or have been described else-
where (5). The appropriate Ig isotype 
subclass control is always to the left of -:; 
the specific antibody profile. The re- :...; 
suIts are representative of three sepa-
rate experiments. 
NLDC145 
C3H 
~~ll 
" 
~ 
~el ap \01 I'rl J I'd'" 
BALB/c 
MHC II B7-Z NLDC145 MHC II B7-Z 
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TABLE 1. Influence of donor-specific GM-CSF-stimulated DC progenitors (B7-2-) on BI0 cardiac allograft survival in C3H micea 
Group Cells injected Graft survival times Mean:tlSD MST (day -7) n <days) 
A None (media control) 8 8 (x3), 12, 13 (X2), 9, 10 10.l::t2.2 9.5 
B Fresh BI0 bone marrow cells 4 12 (X4) 12 12 
(allogeneic) 
Cultured cells 
C BI0 (B7-2+) (allogeneic) 17 4 (X5), 5 (x3), 7 (X2), 8 (X2), 7.5::t4.1 7b 
9, 10, 14 (X2), 15 
D BI0 (B7-2-) (allogeneic) 15 7,19 (X4), 20, 22 (X2), 23, 23.3::'::5.5 22"·d 
26,27,29,30,35,67 
E C3H (B7-2-) (syngeneic) 4 12 (x2), 13 (X2) 12.5::tO.6 12.5 
F BALBIc (B7-2-) (third party) 9 7,12,16 (x2), 17 (X3), 19, 20 15.7:t3.9 16.5 
a Cells (2x 106 Lv.) were injected 7 days before heterotopic (B10-...C3H) heart transplantation. MSTs were compared using the Kruskal-
Wallis test. Pairwise comparison was done using the Wilcoxon sum rank test. 
b P<O.OI compared with groups D and F. 
c P<0.003 compared with groups C and E. 
d P<O.OI compared with group F. 
(BALB/c) B7-2- BM-derived DC also prolonged BlO heart 
graft survival, although the MST (16.5 days) was signifi-
cantly shorter (P<O.01) than that achieved with donor-spe-
cific B7 -2 - DC. 
MLR and cytotoxic T lymphocyte assays. To gain further 
insight into anti-donor immune responsiveness of C3H recip-
ients of B7-2- or B7-2+ B10 BM-derived DC, 2x106 cells 
were injected intravenously, and 7 days later (the time of 
heart transplant), MLR and cytotoxic T lymphocyte (CTL) 
assays were performed using recipient T cells as responder/ 
effector cells. Figure 2 shows the MLR responses obtained 
against allogeneic (B10; H2b ), syngeneic (C3H; H2k), and 
third-party (BALBIc; H2d ) stimulator cells at various S:R cell 
ratios. T cells from C3H mice injected with B10 B7-2+ DC 
showed marked proliferative responses to donor, a much 
milder response to third-party cells, and no reactivity against 
syngeneic cells. By contrast, the animals that received B7-2-
B10 DC progenitors showed very little evidence of MLR re-
sponses to donor and no reaction against third-party stimu-
lators. A similar pattern of anti-donor reactivity was ob-
tained using CTL assays (Fig. 3). T cells from mice injected 7 
days earlier with 2x106 B10 B7-2+ DC exhibited much 
higher CTL responses to donor targets than animals given 
B7-2- cells. A moderate CTL response to third-party targets 
was found in the former, but not in the latter, group of 
animals. The third-party response suggested a degree of an-
tigenic cross-reactivity between B10 (H2b+) and BALB/c 
(H2d +) cells or between the target cell lines expressing the 
respective histocompatibility antigens. 
Expression of B7-1 and B7-2 molecules on donor-derived 
cells within recipient lymphoid tissue. To determine whether 
the B7 -2 - BM-derived DC progenitors expressed cell surface 
B7 family molecules following their systemic administration. 
2X 106 B10 B7-2- cells were injected intravenously into naive 
C3H recipients. One to 7 days later, the animals were killed. 
Spleens were removed and analyzed by two-color immuno-
histochemical staining for the expression of B7 -I and B7 -2 on 
donor-derived (H2b+; I-A +) cells. As shown in Figure 4, I_Ab+ 
cells that also expressed B7-1 or B7-2 could be detected in 
T-dependent areas within 7 days of B7-2 - cell injection. 
Thus, although B10 B7-2- DC induced only low levels of 
T-cell priming and prolonged B10 heart graft survival, B7 
family molecule expression could nevertheless be detected on 
these cells in normal nonimmunosuppressed recipients 
within 1 week of their administration. 
DISCUSSION 
The present findings show, for the first time, that pretreat-
ment of mice with MHC class 11+ costimulatory molecule (B7 
family) "deficient" DC progenitors can prolong vascularized 
organ allograft survival. The systemic administration of 
these donor-BM-derived APC 1 week before cardiac trans-
plantation resulted in temporary prolongation of graft sur-
vival, in the absence of immunosuppressive drug therapy. 
MST was prolonged significantly from 9.5 days (untreated 
controls) to 22 days; a less marked but statistically signifi-
cant prolongation of heart allograft survival was also ob-
tained by injection of third-party DC progenitors. In addition, 
ex vivo analysis of host T-cell responses to donor alloantigens 
revealed only weak MLR and CTL function in animals pre-
treated with DC progenitors compared with those primed 
with "mature" (B7-1 +, B7-2+) DC. The results are consistent 
with the capacity of the BM-derived DC progenitors to induce 
T-cell hyporesponsiveness to alloantigen in vitro. They are 
also in agreement with our recent finding (25) that, using a 
similar cell dose and treatment schedule, DC progenitors 
prolong the survival of pancreatic islet allografts. 
Considerable insight has recently been gained into the role 
of costimulation in T-lymphocyte activation. Costimulatory 
signals delivered to T cells by APC are neither antigen spe-
cific nor MHC restricted, but they determine the outcome of 
T cell receptor signaling because they mediate cytokine se-
cretion. Co-ligation of the T-cell CD28/CTLA-4 receptors (an 
essential stimulus of T-cell activation) (26) by B7 family 
molecules (27-29) results in IL-2 production and T-cell pro-
liferation (26, 28, 29). Although DC express several other 
important intercellular adhesion and costimulatory mole-
cules, including CDUa, CD40, CD44, CD48/58, and CD54, 
B7-2 (CD86) appears to be the major CD28/CTLA-4 ligand 
and accounts for the costimulation provided by this pathway 
during in vitro T-cell responses. The early and sustained 
expression ofB7-2 mRNA (within 8 hr) <before maximal B7-1 
expression) in activated murine B cells (30) suggests that it 
may provide a critical signal involved in the decision between 
activation or inactivation of T cells within 24 hr of stimula-
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FIGURE 2. Mixed leukocyte responses of splenic T cells from normal 
C3H mice injected intravenously 7 days previously with either 2 x 106 
(e) 810 8M-derived 87-2- DC progenitors or (.) 87-2+ DC. The 
C3H T cells were stimulated for 3 days with either 810 (allogeneic), 
C3H (syngeneic), or 8AL8/c (third party) spleen cells at various S:R 
ratios. Results are mean counts per minute :!: lSD and are repre-
sentative of three separate experiments. 
tion (31,32). Moreover, APC from B7-1 "knockout" mice that 
express B7-2 are competent APC (30). 
MHC class II+ DC progenitors that are B7-2- may (as is 
the case with inhibition of B7-2 expression 127]) allow T cell 
receptor-mediated signaling events to occur, but inhibit the 
distinct costimulatory signaJ(s) that is necessary for optimal 
cytokine production and cytokine-dependent T-cell prolifera-
tion. Thus. antigen presentation by APC that are unable to 
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FIGURE 3. CTL responses of splenic T cells from normal C3H <H2k) 
mice injected intravenously 7 days previously with either 2x 106 (e) 
810 <H2b ) 8M-derived 87-2- DC progenitors or (.) 87-2+ DC. 
Freshly isolated C3H spleen cells were cultured for 6 days with 
y-irradiated 810 spleen celis, as described in Materials and Methods, 
then used as effectors against MCr-labeled allogeneic EL-4 (H2b), 
syngeneic Rl.l <H2k), or third-party PS15 <H2d ) target cells. The 
results are expressed as mean '7c specific lysis in triplicate cultures. 
deliver adequate costimulatory signals induces neither of the 
gene transcription factors NF-AT or NF-kB (33). 
In principle, the induction of irreversible T-cell anergy to 
donor-specific alloantigens in vivo (tolerance) would elimi-
nate the need for potentially toxic, nonspecific immunosup-
pressive agents. which currently constitute first choice anti-
rejection therapy. Thus. there has been considerable interest 
in evidence that blockade of the B7-CD28 T-cell costimula-
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FIGURE 4. Two color immunofluorescence labeling of B7-2 (C086) on donor-derived DC (l-Ab +) within the T-dependent area of allogeneic 
spleen 7 days after the injection of GM-CSF-stimulated DC progenitors (B7-2-). (A) B7-2+ cells are stained green (FITC-conjugated 
secondary mAb) and, in addition, (8) donor MHC class II+ cells (l-Ab +) are stained red (steptavidin-conjugated Cy 3.18). (B) Both 
double-positive cells and less brightly staining (87-2-) donor cells (I-Ab+; arrows) are visible (magnification x250). 
tory pathway may be both necessary and sufficient to induce 
antigen-specific T-cell anergy (34). Combination of anti-B7 
mAb and cyclosporine induces alloantigen-specific anergy in , 
vitro (35). CTLA4-Ig, a fusion protein that blocks the CD28-
mediated costimulatory signal, inhibits T-cell proliferation in 
allogeneic MLR (27, 41), and induces hyporesponsiveness to 
alloantigen in vitro (11). Moreover, it prolongs the survival of 
MHC-mismatched cardiac (36, 37) and renal (38) allografts in 
rats and induces donor-specific tolerance to skin grafts in 
cardiac-allografted mice (39), Propagation of B7-2- "imma-
ture" DC with the capacity to induce hyporesponsiveness to 
donor alloantigens has significant in vivo implications. Con-
ceivably, the tolerogenicity of the transplanted mouse liver, a 
potential hematopoietic organ (40, 41), may be linked, at 
least in part, to the release of potentially T cell-anergizing 
DC progenitors from the graft. This is likely to occur under 
the influence of locally produced GM-CSF (42) and possibly 
other DC growth-promoting cytokines, such as c kit-ligand, 
IL-3, and Flt3 ligand. Others have suggested that in 'immu-
nosuppressed recipients. vascularized allogeneic bone grafts. 
with their content of DC progenitors, may induce both sub-
stantial chimerism and perhaps tolerance at the level of the 
"immature" DC-host T-cell interaction (43). The failure of the 
B7-2- DC progenitors in this study to induce indefinite car-
diac allograft survival may reflect instability of specific T-cell 
hypo responsiveness in recipients of DC progenitors that have 
not received any form of immunosuppressive therapy. Graft 
rejection may also reflect the eventual in vivo up-regulation 
of at least one set of costimulatory \ 87) molecules observed 
on some of these donor-derived cells within a week of their 
injection. Regulation of the expression of other molecules, 
e.g., CD40 or CD54 (intercellular adhesion molecule-l) is also 
likely to be important. It seems clear that considerations of 
the cellular therapy of allograft rejection using "immature" 
donor-derived DC progenitors should include further analy-
sis of the influence of cell dosage, frequency of injection, and 
temporal relationship between cell injection and organ trans-
plantation. The use of adjunctive immunosuppression with 
drugs or monoclonal antibodies should also be explored. Al-
ternatively, molecular (gene therapy) approaches geared to 
inhibit or block costimulatory molecule expression on donor 
APC offer exciting possibilities. 
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